Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Spruss

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
International Journal of Pharmaceutics|March 7, 2006
Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipidsC Guse, S Koennings, A Maschke, et al.
Archives of Oral Biology|May 27, 2021
Histology of human teeth: Standard and specific staining methods revisitedM Widbiller, C Rothmaier, D Saliter, et al.
Archiv Der Pharmazie|September 1, 1995
Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activityR Gust, G Bernhardt, T Spruss, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1990
Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexesH D vom Orde, H Reile, R Müller, et al.
Archiv Der Pharmazie|March 1, 1990
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell lineH Reile, R Müller, R Gust, et al.
Journal of Medicinal Chemistry|January 1, 1988
Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinomaJ Karl, R Gust, T Spruss, et al.
Cancer Treatment Reviews|September 1, 1990
Platinum compounds with estrogen receptor affinityP J Bednarski, R Gust, T Spruss, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexesG Bernhardt, R Gust, H Reile, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell lineG Bernhardt, R Gust, H Reile, et al.
Nature Genetics|February 2, 2000
Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient miceE Orsó, C Broccardo, W E Kaminski, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
International Journal of Pharmaceutics|March 7, 2006
Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipidsC Guse, S Koennings, A Maschke, et al.
Archives of Oral Biology|May 27, 2021
Histology of human teeth: Standard and specific staining methods revisitedM Widbiller, C Rothmaier, D Saliter, et al.
Archiv Der Pharmazie|September 1, 1995
Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activityR Gust, G Bernhardt, T Spruss, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1990
Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexesH D vom Orde, H Reile, R Müller, et al.
Archiv Der Pharmazie|March 1, 1990
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell lineH Reile, R Müller, R Gust, et al.
Journal of Medicinal Chemistry|January 1, 1988
Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinomaJ Karl, R Gust, T Spruss, et al.
Cancer Treatment Reviews|September 1, 1990
Platinum compounds with estrogen receptor affinityP J Bednarski, R Gust, T Spruss, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexesG Bernhardt, R Gust, H Reile, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell lineG Bernhardt, R Gust, H Reile, et al.
Nature Genetics|February 2, 2000
Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient miceE Orsó, C Broccardo, W E Kaminski, et al.
Pageof 5